VXRT - Vaxart stock plummets on underwhelming preliminary COVID-19 study data

Vaxart (VXRT) shares slump ~56% after it announces disappointing preliminary data from its Phase 1 study of VXA-CoV2-1, its oral COVID-19 tablet vaccine candidate.However, the company said that neutralizing antibodies were not detected in most of the subjects who were part of the study.The Phase I study was designed to evaluate the safety and immunogenicity of VXA-CoV2-1 vaccine with multiple dosing schedules. Subjects were divided into three cohorts.The first cohort with 5 subjects received two low doses of vaccine 29 days apart and the remaining cohorts with 15 subjects each received a single low or high dose of the vaccine.From a preliminary pooled analysis of all the cohorts, VXA-CoV2-1 triggered multiple immune responses against SARS-CoV-2 antigens , and there were no severe adverse events reported, the company said.

For further details see:

Vaxart stock plummets on underwhelming preliminary COVID-19 study data